Last Updated : September 22, 2023
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Zydelig | Idelalisib | Follicular Lymphoma | Do not reimburse | Complete | ||
| Zykadia | Ceritinib | Metastatic Non-Small Cell Lung Cancer | Do not reimburse | Complete | ||
| Zykadia (Resubmission) | Ceritinib | metastatic non-small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Zytiga | Abiraterone | Withdrawn | ||||
| Zytiga | Abiraterone acetate | Metastatic Castration Resistant Prostate Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Zytiga (Resubmission) | Abiraterone | Prostate Cancer Resubmission | Withdrawn | |||
| Zytram XL | Tramadol hydrochloride | Pain, acute | Withdrawn | |||
| Zytram XL | Tramadol hydrochloride | Pain, acute | Do not list | Complete |
Last Updated : September 22, 2023